155 related articles for article (PubMed ID: 1175127)
1. Humoral and cell-mediated immune response in patients with malignant melanoma. I. In vitro lymphocyte reactivity to PHA and antigens following immunization.
de Gast GC; The TH; Schraffordt Koops H; Huiges HA; Oldhoff J; Nieweg HO
Cancer; 1975 Oct; 36(4):1289-97. PubMed ID: 1175127
[TBL] [Abstract][Full Text] [Related]
2. Primary immune response to Helix pomatia haemocyanin in malignant melanoma. Relationship between 19S and 7S antibody response and in vitro lymphocyte transformation.
Gast GC; The TH; Schraffordt Koops H; Snijder AM; Huiges HA
Clin Exp Immunol; 1976 Mar; 23(3):491-8. PubMed ID: 947647
[TBL] [Abstract][Full Text] [Related]
3. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
Lieberman R; Wybran J; Epstein W
Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
[TBL] [Abstract][Full Text] [Related]
4. Long-term spontaneous regression of malignant melanoma with visceral metastases. Report of a case with immunologic profile.
Bulkley GB; Cohen MH; Banks PM; Char DH; Ketcham AS
Cancer; 1975 Aug; 36(2):485-94. PubMed ID: 1157014
[TBL] [Abstract][Full Text] [Related]
5. A prospective study of lymphocyte responses to phytohemagglutinin in melanoma patients. (lack o prognostic value of correlation with minimal tumor burden).
Kovarík J; Ninger E; Zemanová D; Lauerová L
Neoplasma; 1980; 27(5):575-82. PubMed ID: 7231613
[TBL] [Abstract][Full Text] [Related]
6. In vitro lymphocyte reactivity and T cell levels in patients with melanoma: correlations with clinical and pathological stage.
Silverman NA; Alexander JC; Potvin C; Chretien PB
Surgery; 1976 Mar; 79(3):332-9. PubMed ID: 1083075
[TBL] [Abstract][Full Text] [Related]
7. Relationship between lymphocyte response to tetanus toxoid and age of lymphocyte donor.
Peel MM; Edsall G; White WG; Barnes GM
J Hyg (Lond); 1978 Apr; 80(2):259-65. PubMed ID: 632566
[TBL] [Abstract][Full Text] [Related]
8. [The immune competence of patients with Crohn's disease (author's transl)].
Tönnesmann E; Bürkle PA; Schäfer B; Federlin K
Klin Wochenschr; 1979 Oct; 57(20):1097-107. PubMed ID: 513603
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of T- and B-cell immunity of regional lymph nodes in patients with skin melanoma and prognosis of the disease].
Serov AA; Kadagidze ZG
Vopr Onkol; 1983; 29(12):18-20. PubMed ID: 6607569
[TBL] [Abstract][Full Text] [Related]
10. The use of oral BCG in the treatment or metastatic malignant melanoma.
Pritchard KI; Cowan DH; Baker MA; Osoba D; Phillips RA; Clark DA
Med Pediatr Oncol; 1976; 2(2):173-81. PubMed ID: 785199
[TBL] [Abstract][Full Text] [Related]
11. Demonstration of lymphocyte blastogenesis--inhibiting factors in sera of melanoma patients.
Rangel DM; Golub SH; Morton DL
Surgery; 1977 Aug; 82(2):224-32. PubMed ID: 877866
[TBL] [Abstract][Full Text] [Related]
12. A prospective study of immune responsiveness in human melanoma. I. Assessment of initial pretreatment status with stage of disease.
Pritchard DJ; Ritts RE; Taylor WF; Miller GC
Cancer; 1978 Jun; 41(6):2165-73. PubMed ID: 306870
[TBL] [Abstract][Full Text] [Related]
13. In vitro lymphocyte reactivity to soluble tumor extracts in Sinclair melanoma swine.
Aultman MD; Hook RR
Int J Cancer; 1979 Nov; 24(5):673-8. PubMed ID: 528082
[No Abstract] [Full Text] [Related]
14. In vitro and in vivo immune response to specific antigens in canine marrow graft recipients.
Abb J; Kolb HJ; Rodt HV; Grosse-Wilde H; Rieder I; Thierfelder S
Z Immunitatsforsch Immunobiol; 1977 Jul; 153(2):152-61. PubMed ID: 71795
[TBL] [Abstract][Full Text] [Related]
15. Sequential evaluation of immunoreactivity in patients with melanoma undergoing surgery and adjuvant therapy.
Dionigi R; Dominioni L; Gnes F; Bonera A; Prati U; Scarponi A; Robustelli Della Cuna G; Pavesi L; Campani M
Tumori; 1980 Feb; 66(1):59-76. PubMed ID: 6966434
[TBL] [Abstract][Full Text] [Related]
16. Lymphocyte-mediated cytotoxicity on human tumor cells in vitro.
Schwenke H; Schönfelder M
Arch Geschwulstforsch; 1975; 45(8):802-9. PubMed ID: 1241765
[TBL] [Abstract][Full Text] [Related]
17. Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; A clinical assessment.
Seigler HF; Shingleton WW; Pickrell KL
Plast Reconstr Surg; 1975 Mar; 55(3):294-8. PubMed ID: 1118487
[TBL] [Abstract][Full Text] [Related]
18. Phytohemagglutinin skin tests in cancer patients.
Zuckerman KS; LoBuglio AF
Cancer; 1977 Jun; 39(6):2355-61. PubMed ID: 266970
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma.
Thurner B; Haendle I; Röder C; Dieckmann D; Keikavoussi P; Jonuleit H; Bender A; Maczek C; Schreiner D; von den Driesch P; Bröcker EB; Steinman RM; Enk A; Kämpgen E; Schuler G
J Exp Med; 1999 Dec; 190(11):1669-78. PubMed ID: 10587357
[TBL] [Abstract][Full Text] [Related]
20. Immunodiagnostics of malignant disease. VI. Electrophoretic mobility test (EMT) in malignant melanoma.
Douwes FR; Spellmann HJ; Mross K; Wolfrum DI
Oncology; 1978; 35(4):163-7. PubMed ID: 81476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
